Longevity Protocol

Overview

Aging is increasingly understood not as an inevitable decline but as a collection of interconnected biological processes that are, at least in principle, modifiable. The hallmarks of aging — genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication — provide specific targets for intervention.

Peptide-based longevity protocols aim to address multiple hallmarks simultaneously, reflecting the interconnected nature of aging biology. This protocol combines four categories of compounds: a telomerase activator (Epithalon), mitochondrial-targeted peptides (MOTS-c and SS-31), and NAD+ restoration strategies that support cellular energy metabolism and sirtuin activity.

The rationale for a multi-target approach is that aging is not driven by a single mechanism. Addressing telomere maintenance without supporting mitochondrial function, or restoring NAD+ without managing cellular senescence, produces an incomplete intervention. This protocol attempts a more comprehensive strategy, though it is important to note that human longevity research for most of these compounds remains in early stages.

Compounds Involved

Protocol Structure

This protocol is designed as a cyclical, long-term strategy rather than a fixed-duration intervention. Different compounds follow different cycling patterns based on their mechanisms and available research.

Epithalon Cycles (Quarterly)

Epithalon:

• Dose: 5–10 mg per day
• Frequency: Once daily
• Duration: 10–20 consecutive days per cycle
• Frequency of cycles: Every 3–4 months (approximately 3–4 cycles per year)
• Injection site: Subcutaneous, abdominal
• Timing: Evening administration is sometimes preferred due to Epithalon's documented effects on melatonin production via the pineal gland
• Rationale: Epithalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide based on Epithalamin, a pineal gland extract studied by Russian gerontologist Vladimir Khavinson. Research has shown it activates telomerase, the enzyme responsible for maintaining telomere length, in human somatic cells. Cyclical administration reflects the pulsatile nature of the research protocols

Mitochondrial Support (Ongoing)

MOTS-c:

• Dose: 5–10 mg per injection
• Frequency: 3–5 times per week
• Injection site: Subcutaneous, abdominal
• Timing: Morning, preferably before exercise on training days
• Cycling: Can be run continuously or in 8-week on, 2-week off cycles
• Rationale: MOTS-c is a mitochondrial-derived peptide encoded in the mitochondrial genome that activates AMPK, improves glucose metabolism, and enhances exercise capacity. Mitochondrial dysfunction is a central hallmark of aging, and MOTS-c levels decline with age

SS-31 (Elamipretide):

• Dose: 0.5–2 mg per day
• Frequency: Once daily
• Injection site: Subcutaneous, abdominal
• Cycling: 4–8 week cycles with 2–4 week breaks
• Rationale: SS-31 concentrates in the inner mitochondrial membrane where it binds cardiolipin, a phospholipid critical for electron transport chain function. By stabilizing cardiolipin, SS-31 supports mitochondrial efficiency and reduces reactive oxygen species (ROS) production at the source. It has been studied in clinical trials for mitochondrial myopathy and heart failure

NAD+ Restoration (Ongoing)

NMN (Nicotinamide Mononucleotide) or NR (Nicotinamide Riboside):

• NMN dose: 250–1000 mg per day, oral
• NR dose: 300–600 mg per day, oral
• Timing: Morning administration is common; some researchers split into morning and midday doses
• Cycling: Generally used continuously, though some practitioners cycle 5 days on, 2 days off
• Rationale: NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for cellular energy metabolism, DNA repair (via PARP enzymes), and sirtuin activation. NAD+ levels decline approximately 50% between ages 40 and 60. NMN and NR are biosynthetic precursors that have been shown to elevate tissue NAD+ levels in human studies

Annual Protocol Calendar

Biomarkers of Aging

Tracking biological age and aging-related biomarkers provides objective assessment of protocol effects:

• Telomere length: Measured via qPCR or Flow-FISH. Assess annually. Epithalon cycles specifically target this marker
• Epigenetic age: DNA methylation-based clocks (Horvath, GrimAge, DunedinPACE) provide biological age estimates. Assess annually
• NAD+ levels: Whole blood or intracellular NAD+ measurement. Assess at baseline and 3 months after starting NAD+ precursors
• Inflammatory markers: hsCRP, IL-6, TNF-alpha. Chronic low-grade inflammation (inflammaging) is a hallmark of aging
• Metabolic markers: Fasting glucose, insulin, HbA1c, HOMA-IR. Metabolic health is tightly linked to aging trajectories
• Hormonal panel: Testosterone/estradiol, DHEA-S, IGF-1, thyroid panel. Hormonal decline tracks with biological aging
• Mitochondrial function: Indirect markers include lactate levels, VO2 max testing, and exercise recovery metrics

Lifestyle Integration

Peptides operate within the context of fundamental lifestyle factors that have substantial evidence for longevity:

• Exercise: Both aerobic and resistance training independently activate many of the same pathways targeted by these peptides (AMPK, mitochondrial biogenesis, autophagy). Exercise is non-negotiable in any longevity strategy
• Caloric optimization: Caloric restriction or time-restricted eating activates sirtuins and AMPK, complementing NAD+ restoration and MOTS-c
• Sleep: Growth hormone secretion, autophagy, and glymphatic clearance occur primarily during deep sleep. See the Sleep Optimization Protocol
• Stress management: Chronic cortisol elevation accelerates telomere shortening and promotes inflammaging
• Environmental toxin reduction: Minimizing exposure to endocrine disruptors, heavy metals, and air pollution reduces the extrinsic aging burden

Important Considerations

• Research maturity varies widely: Epithalon has decades of Russian research but limited Western clinical trials. MOTS-c is a relatively recent discovery with growing but still early-stage human data. SS-31 has undergone clinical trials but primarily for specific disease states. NAD+ precursors have the most robust human trial data of the group.
• Telomerase activation and cancer: Telomerase is also active in cancer cells. The theoretical concern that telomerase activation could promote cancer growth has been discussed extensively in the literature. Epithalon research has not shown oncogenic effects, and some studies suggest anti-cancer properties, but this remains an area requiring ongoing investigation.
• Cost considerations: A comprehensive longevity protocol involving multiple peptides and regular biomarker testing represents a significant financial commitment. Prioritization based on individual aging profiles may be more practical than running all compounds simultaneously.
• No proven life extension in humans: While individual compounds have shown lifespan extension in animal models, no peptide-based longevity protocol has demonstrated verified human lifespan extension. The goal is healthspan optimization — extending the period of healthy, functional life.
• Individual variation: Aging biology varies significantly between individuals. Genetic polymorphisms, baseline health status, and environmental exposures all influence response to longevity interventions.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.